<?xml version="1.0" encoding="UTF-8"?>
<p>Nucleoside analogues are commonly used in the treatment of viral infections and cancer [
 <xref rid="B21-cancers-12-00713" ref-type="bibr">21</xref>]. Following phosphorylation by intracellular kinases, these analogues are structurally similarly to endogenous dNTP. SAMHD1 has been shown to affect the efficacy of nucleoside analogs, either used as antiretrovirals [
 <xref rid="B22-cancers-12-00713" ref-type="bibr">22</xref>,
 <xref rid="B23-cancers-12-00713" ref-type="bibr">23</xref>,
 <xref rid="B24-cancers-12-00713" ref-type="bibr">24</xref>,
 <xref rid="B25-cancers-12-00713" ref-type="bibr">25</xref>,
 <xref rid="B26-cancers-12-00713" ref-type="bibr">26</xref>] or as chemotherapeutic drugs [
 <xref rid="B27-cancers-12-00713" ref-type="bibr">27</xref>,
 <xref rid="B28-cancers-12-00713" ref-type="bibr">28</xref>,
 <xref rid="B29-cancers-12-00713" ref-type="bibr">29</xref>]. Active SAMHD1 catalyzes the hydrolysis and inactivation of a number of different nucleoside analogues [
 <xref rid="B30-cancers-12-00713" ref-type="bibr">30</xref>,
 <xref rid="B31-cancers-12-00713" ref-type="bibr">31</xref>], including cytarabine (Cytosar-U
 <sup>Â®</sup>,Ara-C), a first line therapeutic agent for acute myelogenous leukaemia (AML) and SAMHD1 expression levels were negatively correlated with Ara-C treatment success in individuals with AML [
 <xref rid="B27-cancers-12-00713" ref-type="bibr">27</xref>,
 <xref rid="B29-cancers-12-00713" ref-type="bibr">29</xref>,
 <xref rid="B32-cancers-12-00713" ref-type="bibr">32</xref>].
</p>
